Endocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression.

This study explores the endocannabinoid system's role in migraine and depression. Researchers examined cerebrospinal fluid (CSF) levels of specific endocannabinoids in 194 episodic migraine patients. The participants included 97 individuals with aura and 97 without aura. They were compared to 94 healthy volunteers, matched by age and sex. Micro-liquid chromatography-tandem mass spectrometry was used for analysis. Results showed no significant differences in endocannabinoid levels between migraine patients and controls. Specifically, levels of N-arachidonoylethanolamine (AEA), 2-arachidonoylglycerol (2-AG), and docosahexaenoylethanolamine (DHEA) were similar across groups. However, higher levels of 2-AG correlated positively with depressive symptoms. The findings suggest that CSF endocannabinoids may not effectively distinguish between migraine patients and controls. Instead, the link between 2-AG levels and depression highlights important connections between these conditions. Overall, this research adds insights into the complex relationship between migraines and depression. Clinical relevance: This research indicates that 2-AG levels could help understand migraine and depression connections.